Ruconest Alternatives Compared
Ruconest | Haegarda | Orladeyo |
|
---|
Ruconest (conestat alfa) | Haegarda (C1 esterase inhibitor (human)) | Orladeyo (berotralstat) |
|
|||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Prescription only
Ruconest is used to treat hereditary angioedema (HAE) in adults and adolescents and is given by slow intravenous injection over 5 minutes, usually by a healthcare professional. Headache, nausea, and... View more |
Prescription only
Haegarda works by replacing missing C1 protein in the blood of adults and children over the age of 6 with hereditary angioedema (HAE) preventing the generation of bradykinin and angioedema attacks... View more |
Prescription only
Orladeyo is an oral, once-daily medication that is taken to reduce angioedema attacks in adults and children over the age of 12 with HAE. It is the only oral preventive currently available (the... View more |
Related suggestions Hereditary Angioedema
|
|||||||||||||||||||||||
More about Ruconest (conestat alfa) | More about Haegarda (C1 esterase inhibitor (human)) | More about Orladeyo (berotralstat) | ||||||||||||||||||||||||
Ratings & Reviews | ||||||||||||||||||||||||||
Ruconest has an average rating of 10.0 out of 10 from a total of 3 ratings on Drugs.com. 100% of reviewers reported a positive effect, while 0% reported a negative effect. |
Haegarda has an average rating of 8.0 out of 10 from a total of 1 ratings on Drugs.com. 100% of reviewers reported a positive effect, while 0% reported a negative effect. |
Orladeyo has an average rating of 6.7 out of 10 from a total of 3 ratings on Drugs.com. 33% of reviewers reported a positive effect, while 0% reported a negative effect. |
||||||||||||||||||||||||
Drug Class | ||||||||||||||||||||||||||
Side Effects | ||||||||||||||||||||||||||
See also: Ruconest side effects in more detail. |
See also: Haegarda side effects in more detail. |
See also: Orladeyo side effects in more detail. |
||||||||||||||||||||||||
Generic Availability | ||||||||||||||||||||||||||
N/A |
N/A |
|||||||||||||||||||||||||
Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all Ruconest prices |
View all Haegarda prices |
View all Orladeyo prices |
||||||||||||||||||||||||
Dosage Forms Available | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
Brand Names | ||||||||||||||||||||||||||
N/A |
Other C1 esterase inhibitor (human) brands include: Berinert, Cinryze |
N/A |
||||||||||||||||||||||||
Half Life The half-life of a drug is the time taken for the plasma concentration of a drug to reduce to half its original value. | ||||||||||||||||||||||||||
3 hours |
152 hours |
152 hours |
||||||||||||||||||||||||
CSA Schedule ** View glossary of terms | ||||||||||||||||||||||||||
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
Pregnancy Category | ||||||||||||||||||||||||||
Category B
No proven risk in humans
See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||||||||||||||||||
Drug Interactions | ||||||||||||||||||||||||||
A total of 48 drugs are known to interact with Ruconest:
|
A total of 49 drugs are known to interact with Haegarda:
|
A total of 452 drugs are known to interact with Orladeyo:
|
||||||||||||||||||||||||
Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||||||||
Disease Interactions | ||||||||||||||||||||||||||
First Approval Date | ||||||||||||||||||||||||||
N/A |
N/A |
December 03, 2020 |
||||||||||||||||||||||||
WADA Class View World Anti-Doping Agency classifications. | ||||||||||||||||||||||||||
N/A |
N/A |
N/A |
||||||||||||||||||||||||
More Information | ||||||||||||||||||||||||||
Patient resources | ||||||||||||||||||||||||||
Professional Resources | ||||||||||||||||||||||||||
Related Treatment Guide | ||||||||||||||||||||||||||
** The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.